bluuebunny/crossref_metadata_2025_split huggingface dataset:
Face repairing based on transfer learning method with fewer training samples: application to a Terracotta Warrior with facial cracks and a Buddha with a broken nose
Authors: Zhu Jian , Fang Bowei , Chen Tianning , Yang Hesong 
Published: June 2024

Abstract
In this paper, a method based on transfer learning is proposed to recover the three-dimensional shape of cultural relics faces from a single old photo. It can simultaneously reconstruct the three-dimensional facial structure and align the texture of the cultural relics with fewer training samples. The UV position map is used to represent the three-dimensional shape in space and act as the output of the network. A convolutional neural network is used to reconstruct the UV position map from a single 2D image. In the training process, the human face data is used for pre-training, and then a small amount of artifact data is used for fine-tuning. A deep learning model with strong generalization ability is trained with fewer artifact data, and a three-dimensional model of the cultural relic face can be reconstructed from a single old photograph. The methods can train more complex deep networks without a large amount of cultural relic data, and no over-fitting phenomenon occurs, which effectively solves the problem of fewer cultural relic samples. The method is verified by restoring a Chinese Terracotta Warrior with facial cracks and a Buddha with a broken nose. Other applications can be used in the fields such as texture recovery, facial feature extraction, and three-dimensional model estimation of the damaged cultural relics or sculptures in the photos.
Byzantine wall paintings from San Marco d’Alunzio, Sicily: non-invasive diagnostics and microanalytical investigation of pigments and plasters
Authors: Alberghina Maria Francesca , Zicarelli Maria Antonietta , Randazzo Luciana , Schiavone Salvatore , La Russa Mauro Francesco , Labriola Maria , Rigaglia Davide , Ricca Michela 
Published: June 2024

Abstract
A diagnostic investigation was carried out on twelfth century Byzantine wall paintings preserved in the Museum of Byzantine and Norman Culture and Figurative Arts of San Marco d’Alunzio (Messina, Italy) on the occasion of recent restoration works. First, the wall paintings were analyzed using portable X-Ray Fluorescence (p-XRF) and Fiber Optics Reflectance Spectroscopy (FORS) to obtain a non-invasive preliminary identification of the original palette. Then, five fragments were sampled for a micro-stratigraphy study using Digital Optical Microscope (DOM), Polarizing Optical Microscope (POM), and Scanning Electron Microscopy (SEM) combined with Energy Dispersive X-ray Spectrometry (EDS) to characterize the mortars and the blue and black pigments non unequivocally identified through non-invasive techniques. The palette included mainly earthen pigments like red and yellow ochres, green earth, and more valuable lapis lazuli blue applied on a bone black layer; while the analysis of mortars found on the different apses showed the same manufacturing technique and constitutive materials: lime-based binder with the addition of quartz, and rare calcareous lithic fragments as aggregate. The obtained results shed light on the pictorial technique used for the wall paintings and allowed us to compare the Sicilian pictorial cycle with the coeval Byzantine wall paintings preserved in Sardinia and Southern Italy.
Survival rate of patient with glioblastoma: a population-based study
Authors: Sabouri Masih , Dogonchi Aref Famili , Shafiei Mehdi , Tehrani Donya Sheibani 
Published: June 2024

Abstract
Introduction
Glioblastoma, as the most common and lethal primary malignant brain tumor, has estimated mean survival of 15 months. GBM is reported more in men. Malignant glioma is the cause of 2.5% of cancer deaths. The standard therapy for patients with newly diagnosed GBM includes tumor resection surgeries, followed by radiotherapy and chemotherapy. The prognosis of glioma is a major challenge, and the outcome of GBM has remained almost unchanged for past years. The present study aimed to determine patient survival.

Methods
Patients with glioblastoma tumors who visited Al-Zahra and Kashani hospitals from 2013 to 2021 were included in this study. All patients were classified with morphological codes according to the International Classification of Diseases for Oncology. The patients’ information was recorded in the checklist, and then, the patients were followed up by phone. The data were measured regarding age, gender, exposure to chemicals, body mass index (BMI), and survival from the patient's surgery to death. Several questions were asked from the families of deceased patients and survivors based on the KPS Status Scale. Finally, the sample was analyzed with SPSS version 26.

Result
The patient's mean age was 51.93 years, and the male–female ratio was 1:1.7. The patients' mean overall survival was 29 months and a total of 9 patients survived. There was a significant difference between the age groups in terms of 1-year survival so that more deaths were observed in the age group of more than 50 years. The mean tumor size was 5.2 ± 2.1 cm. The survival analysis indicated that the temporal lobe was more than the other in 2-year survival. The most common symptom of patients before surgery was headache (31.8%) followed by motor dysfunction. The 1-year, 2-year, 5-year, and overall survival of the patients was 4.5%, 18.38%, 37.13%, and 33.68%, respectively.

Conclusions
The results of the present study indicated that the patients' survival improved over time with the advancement of adjuvant therapies. Therefore, if patients care get better for the first year after surgery, their survival will improve from the second year after the operation.
Dissemination and implementation research coordination and training to improve cardiovascular health in people living with HIV in sub-Saharan Africa: the research coordinating center of the HLB-SIMPLe Alliance
Authors: Tetteh Emmanuel K. , Effah William , Fuentes Lisa de las , Steger-May Karen , Goss Charles W. , Dowdy David W. , Huffman Mark D. , Williams Makeda J. , Tonwe Veronica , Bansal Geetha P. , Geng Elvin H. , Dávila-Román Victor G. , Rice Treva , Schechtman Kenneth B 
Published: June 2024

AbstractAs global adoption of antiretroviral therapy extends the lifespan of People Living with HIV (PLHIV) through viral suppression, the risk of comorbid conditions such as hypertension has risen, creating a need for effective, scalable interventions to manage comorbidities in PLHIV. The Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB-SIMPLe) Alliance has been funded by the National Heart, Lung, and Blood Institute (NHLBI) and the Fogarty International Center (FIC) since September 2020. The Alliance was created to conduct late-stage implementation research to contextualize, implement, and evaluate evidence-based strategies to integrate the diagnosis, treatment, and control of cardiovascular diseases, particularly hypertension, in PLHIV in low- and middle-income countries (LMICs).The Alliance consists of six individually-funded clinical trial cooperative agreement research projects based in Botswana, Mozambique, Nigeria, South Africa, Uganda, and Zambia; the Research Coordinating Center; and personnel from NIH, NHLBI, and FIC (the Federal Team). The Federal Team works together with the members of the seven cooperative agreements which comprise the alliance. The Federal Team includes program officials, project scientists, grant management officials and clinical trial specialists. This Alliance of research scientists, trainees, and administrators works collaboratively to provide and support venues for ongoing information sharing within and across the clinical trials, training and capacity building in research methods, publications, data harmonization, and community engagement. The goal is to leverage shared learning to achieve collective success, where the resulting science and training are greater with an Alliance structure rather than what would be expected from isolated and unconnected individual research projects.In this manuscript, we describe how the Research Coordinating Center performs the role of providing organizational efficiencies, scientific technical assistance, research capacity building, operational coordination, and leadership to support research and training activities in this multi-project cooperative research Alliance. We outline challenges and opportunities during the initial phases of coordinating research and training in the HLB-SIMPLe Alliance, including those most relevant to dissemination and implementation researchers.
Targeting small druggable compounds against 3RZE histamine H1 receptor as potential of anti-allergic drug applying molecular modeling approach
Authors: Akram Adeel , Su Chia-Hung , Fu Chun-Chong 
Published: June 2024

Abstract
Background
Allergic disorders, prevalent global health concerns, afflict a substantial portion of the world’s population. These maladies result from an exaggerated immune system response to ordinarily innocuous substances, such as pollen, dust mites, and specific dietary components. Clinical manifestations of this heightened immune response include itching, swelling, and respiratory impairment, often accompanied by releasing mediators like histamine. The pathophysiological mechanisms of allergy disorders are intricate, arising from a complex interplay between genetic and environmental factors. While clinical presentations may vary, all allergy conditions share a common foundation in the dysregulated immune response to allergens.

Result
The current aim of this study was to identify innovative anti-allergic agents capable of inhibiting histamine and effectively mitigating allergic reactions by utilizing the computer-aided drug design approach by discovery studio (DS) 2022 v 23.1.1 package. The overarching aim was identifying potential drug candidates targeting the active site within the histamine H1 receptor complex; therefore, a collection of 4000 small druggable compounds was curated from ZINC, PubChem, and DRUG BANK databases sources. Four compounds appeared as promising candidates after assessing docking scores and binding energies. Notably, Compound ID 34154, recognized as tymazoline, showed the highest affinity for the H1 receptor of 3RZE, suggesting it may be the most promising choice for more research. Further chemoinformatic and ADMET (absorption, distribution, metabolism, excretion, and toxicity) analyses were conducted to assess the drug-like qualities of this chosen molecule. In addition, bioisosteric substitution techniques were employed to enhance tymazoline’s ADMET characteristics.

Conclusion
Tymazoline shows strong binding affinity with 3RZE and verified all the drug-likeness criteria to inhibit the allergic disorders. Furthermore, molecular dynamics (MD) studies corroborated tymazoline’s potential as an anti-allergic agent, demonstrating contact between the ligand and the receptor that is well defined and stable.
Neuroleptic malignant syndrome with acute renal failure associated with rhabdomyolysis: a case report
Authors: Sharma Sunakshi , Bhat Sanjay , Ahmed Zahoor 
Published: June 2024

AbstractNeuroleptic malignant syndrome is a rare, life-threatening neurologic emergency characterized by fever, rigidity, autonomic instability, mental status changes, and an elevated creatine kinase level. It often occurs shortly after the initiation of neuroleptic treatment, or after a dose increase. The management of patients with NMS is based upon clinical severity and includes supportive care and withdrawal of antipsychotic agents and agents like bromocriptine and dantrolene. Complications include acute renal failure associated with rhabdomyolysis, respiratory failure, electrolyte imbalance, hepatic failure, seizures from hyperthermia, metabolic derangements, etc.
Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials.
Authors: Qureshi Zaheer , Altaf Faryal , Jamil Abdur , Siddique Rimsha 
Published: June 2024

1034 Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) that has shown promise in treating metastatic HER2+ and HER2-low breast cancer. This updated systematic review and meta-analysis aimed to evaluate the safety and efficacy of T-DXd in this patient population, integrating data from the latest clinical trials. Methods: We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search was conducted across PubMed, Scopus, and Web of Science up to January 2024, focusing on clinical trials that assessed T-DXd’s efficacy and safety. Eligibility criteria were based on the PICOS framework, and selected studies underwent rigorous quality assessment and data extraction. The primary outcomes were progression-free survival (PFS), overall survival (OS), and the incidence of adverse events. A random-effects meta-analysis was performed to synthesize the data. Results: Seven studies involving 2,201 patients met the inclusion criteria. The pooled analysis revealed that T-DXd significantly improved PFS (OR 0.37, 95% CI 0.27–0.52), indicating a robust efficacy in slowing disease progression. However, treatment was associated with an increased risk of anemia (OR 2.10, 95% CI 1.36–3.25), fatigue (OR 1.56, 95% CI 1.21–2.02), nausea (OR 6.42, 95% CI 4.37–9.42), vomiting (OR 6.21, 95% CI 3.14–12.25), constipation (OR 2.26, 95% CI 1.53–3.34), and notably, drug-related interstitial lung disease (ILD) (OR 10.89, 95% CI 3.81–31.12). The efficacy outcomes demonstrated significant heterogeneity, which was addressed through sensitivity analysis. Conclusions: T-DXd shows significant efficacy in treating metastatic HER2+ and HER2-low breast cancer, offering a valuable therapeutic option for patients with advanced disease. However, the treatment is associated with notable adverse events, including a heightened risk of ILD. These findings underscore the need for careful patient selection, monitoring, and management strategies to mitigate risks. Future research should focus on optimizing treatment protocols and exploring strategies to enhance safety profiles.
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Authors: Motzer Robert J. , Penkov Konstantin , Uemura Hirotsugu , Campbell Matthew T , Kollmannsberger Christian K. , Lee Jae-Lyun , Venugopal Balaji , Van Den Eertwegh Alfonsus , Negrier Sylvie , Gurney Howard , Albiges Laurence , Berger Raanan , Haanen John , Rini Brian I. , Larkin James , Schmidinger Manuela , Sandner Robin , Wang Jing , Di Pietro Alessandra , CHOUEIRI Toni K. 
Published: June 2024

4508 Background: The JAVELIN Renal 101 (NCT02684006) phase 3 trial compared first-line treatment with avelumab + axitinib vs sunitinib in aRCC. The trial previously met one of its primary objectives by showing significantly longer progression-free survival (PFS) with avelumab + axitinib vs sunitinib in pts with PD-L1+ tumors; longer PFS, higher objective response rate (ORR), and an acceptable safety profile were also observed in the overall population. OS data were immature. Here we report the final analysis. Methods: Pts with untreated aRCC (any IMDC risk score) were randomized 1:1 to avelumab + axitinib or sunitinib. OS and PFS (by blinded independent central review) in pts with PD-L1+ tumors (SP263 assay) were independent primary endpoints. OS and PFS in the overall population were key secondary endpoints; response and safety were also analyzed. Results: Of 886 pts randomized, 560 (63.2%) had PD-L1+ tumors. At data cutoff (August 31, 2023), median follow-up in the avelumab + axitinib and sunitinib arms was 73.7 and 73.6 months, respectively (≥68 months in all pts). Final efficacy data are shown in the Table. In the avelumab + axitinib and sunitinib arms, grade ≥3 TRAEs occurred in 66.8% vs 61.5%, respectively. Second-line therapy was received by 58.1% vs 69.4%, including a PD-(L)1 inhibitor in 18.8% vs 53.6%, respectively. Conclusions: The JAVELIN Renal 101 trial provides the longest follow-up for immune checkpoint inhibitor + tyrosine kinase inhibitor combination treatment from a phase 3 trial reported to date. OS analyses favored avelumab + axitinib vs sunitinib but did not reach statistical significance. PFS was longer with avelumab + axitinib vs sunitinib, and responses were durable in a subset of pts. Final analysis results confirm the long-term efficacy and manageable safety profile of avelumab + axitinib treatment in pts with aRCC. Clinical trial information: NCT02684006 . [Table: see text]
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).
Authors: Zarba Martin , Ferrier Evan , Wells Connor , El Zarif Talal , Basappa Naveen S. , Ebrahimi Hedyeh , McKay Rana R. , Wood Lori , Beuselinck Benoit , Suárez Cristina , Takemura Kosuke , Lalani Aly-Khan A. , Li Haoran , Spain Lavinia Anne , Templeton Arnoud J. , Powles Thomas , Bjarnason Georg A. , de Velasco Guillermo , CHOUEIRI Toni K. , Heng Daniel Yick Chin 
Published: June 2024

4514 Background: The role of immunotherapy combinations in mRCC with IMDC favorable risk is controversial. A very favorable subgroup of favorable risk patients (primary diagnosis to systemic therapy ≥3yr, Karnofsky Performance Status 90 or 100% and absence of brain, liver, or bone metastasis) has been described by Schmidt A. et al., which require characterization in the immuno-oncology combination era. Methods: Using the IMDC, we selected mRCC patients with IMDC favorable risk who started systemic therapy during 2016-2023 and examined the favorable risk group and the subset of very favorable risk patients. First line systemic therapy was divided into 3 groups: Ipilimumab + Nivolumab (IPI/NIVO), combination of anti PD1/PDL1 and VEGF (IO-VEGF) (Pembrolizumab and Axitinib or Lenvatinib, Avelumab and Axitinib, or Nivolumab and Cabozantinib), and Vascular endothelial growth factor (VEGF) inhibitors (Pazopanib or Sunitinib). The primary outcomes were 2-year overall survival (2y OS) in the favorable and very favorable risk population. Secondary outcomes included Response Rate (RR), treatment duration (TD) and time to next treatment (TTNT). We used unadjusted survival rates at 2 years, with Cox regression model with TKI mono as reference. Results: 611 favorable risk patients were eligible for analysis, of which 165 (26.9%) had very favorable risk disease. Median age at diagnosis was 62 years, 73.8% were male, 87.1% had clear cell histology, 5% had sarcomatoid features, and 97,2% had a prior nephrectomy. With a median follow up of 33 months, outcomes are summarized in the table. Conclusions: No significant difference in survival between different treatment regimens in the favorable risk population was detected yet. In the very favorable risk population, there was a statistically significant decrease in 2 year overall survival with IPI-NIVO (HR 3.19) which, if validated, could underline the necessity of targeting the VEGF pathway in this population. Further prospective trials and longer follow-up are required to confirm these findings. [Table: see text]
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).
Authors: Aggarwal Rahul Raj , Rottey Sylvie , Bernard-Tessier Alice , Mellado-Gonzalez Begoña , Kosaka Takeo , Stadler Walter Michael , Sandhu Shahneen , Yu Brian , Shaw Crystal , Ju Chia-Hsin , Thompson Corbin , Aparicio Ana 
Published: June 2024

5012 Background: NEPC is an aggressive form of prostate cancer with poor prognosis and no standard treatment approach. NEPC can be characterized by late, treatment-emergent transformation from adenocarcinoma to high-grade neuroendocrine carcinoma (NEC), in 10–15% of mCRPC patients (pts). DLL3 is overexpressed in high-grade NECs, including NEPC, and minimally expressed on normal tissue. Tarlatamab, a bispecific T-cell engager immunotherapy with clinical activity in small cell lung cancer (SCLC), binds DLL3 and CD3 resulting in T-cell mediated tumor lysis. Here, we report primary analysis data of tarlatamab in NEPC (NCT04702737). Methods: This is an open-label phase 1b study evaluating tarlatamab monotherapy in adult (≥18 years [y]) pts with metastatic de novo or treatment-emergent NEPC by histologic, genomic, or immunohistochemistry (IHC) criteria. The starting dose was the highest safe and tolerable dose in the phase 1 SCLC trial (NCT03319940). Safety was the primary objective; anti-tumor activity and pharmacokinetics were secondary objectives. Exploratory analysis of DLL3 expression was assessed by IHC using the Ventana SP347 assay. Results: As of 28 March 2023, 40 pts received ≥1 tarlatamab dose (1 mg step dose, 100 mg target dose). Median (range) age was 64.5 (43–83) y, prior lines of therapy was 3 (1–9), prostate specific antigen at baseline was 0.2 (0.0–5000.0) μg/L. Treatment-related adverse events (TRAE) occurred in all patients, with no fatal TRAE. Most common TRAEs were cytokine-release syndrome (CRS; 65.0%), pyrexia (52.5%) and dysgeusia (42.5%). CRS occurred primarily in treatment cycle 1; events were mostly grade 1–2 (one grade 3 event). Treatment discontinuation due to TRAE was low (7.5%). Tarlatamab serum exposures were consistent with tarlatamab SCLC studies. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was 10.5% (95% CI, 2.9, 24.8); median progression free survival (mPFS) was 1.9 months (m) (95% CI, 1.7, 3.5). Retrospective DLL3 IHC analysis showed that 18 of 32 (56.3%) biopsy evaluable pts had ≥1% DLL3 tumor positivity (DLL3+). As of 24 January 2024, ORR in DLL3+ pts was 22.2% (95% CI, 6.4, 47.6); durations of response in the 4 pts with response were 25.8 m, 9.2 m, 5.5 m, 3.7 m; mPFS in DLL3+ pts was 3.75 m (95% CI, 1.87, 11.01). Efficacy is shown in Table. Conclusions: Findings from this phase 1 study of tarlatamab in pts with NEPC demonstrated manageable safety with encouraging anti-tumor activity in DLL3 expressing NEPC. Further investigation is ongoing. Clinical trial information: NCT04702737 . [Table: see text]
Implications of HPV infection on survival outcomes in patients with penile squamous cell carcinoma: Insights from a nationwide study.
Authors: Garje Rohan , Ganiyani Mohammad Arfat , Khosla Atulya Aman , Ahmad Shahzaib , Podder Vivek , Bellur Shreyas S , Jayram Diya , Jatwani Karan , Ahluwalia Manmeet Singh 
Published: June 2024

5045 Background: Human Papilloma Virus (HPV) infection is a favorable prognostic marker in certain cancers, particularly oropharyngeal and vulvar (SCC). Patients with pSCC have risk profile and clinical course like pSCC. However, the impact of HPV status on survival in pSCC remains uncertain. Methods: We conducted a retrospective study using the National Cancer Database and included patients with pSCC tested for HPV between 2004-2021. Survival outcomes were analyzed and reported as median overall survival (mOS, 95% CI). Multivariate analysis adjusting for age, disease stage, treatment modalities, and comorbidities, was performed using Cox proportional hazards models and reported as hazard ratios (HR, 95% CI). Results: Out of 1371 men with pSCC, 539 (39.3%) were HPV positive (HPV +ve). At diagnosis, most HPV +ve men with pSCC presented with early-stage cancer(I-III), and 6% were stage IV. The mOS for HPV +ve patients was 123.96 months (98.96 - 148.40) vs. 104.38 months (89.13 - 115.98) in HPV negative patients with pSCC (P=0.01). In the adjusted analysis, the presence of HPV infection was associated with HR for death of 0.79 (0.65-0.98; P = 0.03) compared to patients without HPV (table). Conclusions: HPV infection in patients with pSCC is associated with improved survival. These findings highlight HPV status as a prognostic Indicator in pSCC irrespective of clinical profile. Therefore, testing for HPV at the time of diagnosis should be performed routinely in patients with pSCC. [Table: see text]